Visão geral da empresa
A development stage life sciences entity, Nautilus Biotechnology, Inc. focuses its operations on creating platform technology designed to quantify and unlock the complexity of the proteome within the United States market. The corporation specifically develops the Nautilus Voyager Platform, which provides an end-to-end solution comprising instrumentation and software for proteomic analysis. Operating within the Healthcare sector and the Biotechnology industry, the company utilizes specialized scientific infrastructure to advance protein research capabilities. With a market capitalization of $384.76M and an employee base of 130, the firm operates as a mid-sized biotechnology enterprise. The valuation indicates that the market assigns a significant premium to the company's intellectual property and platform technology, suggesting that investors value the long-term potential of the proteomics platform despite the current lack of reported revenue.
Saúde financeira
The company reports no revenue for the trailing twelve months, while recording a net loss of $-59,001,000 and an EBITDA of $-65,084,000. The substantial gap between zero revenue and significant net losses reveals a cost structure dominated by research and development expenditures, regulatory compliance costs, and operational overhead typical of a pre-commercialization stage. Free cash flow stands at $-28,780,124, indicating that the company is currently burning cash to fund its development pipeline and has limited financial flexibility to cover operational expenses without additional capital infusion. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the inability to generate revenue to offset high fixed costs in the absence of sales. On the balance sheet, the company holds $103.41M in cash against $30.02M in debt, resulting in a debt-to-equity ratio of 19.12. Despite the high leverage ratio relative to equity, the absolute debt level is manageable given the substantial cash reserves, suggesting a balance sheet that is less immediately distressed but heavily reliant on future capital raises. The current ratio of 13.32 indicates extremely strong short-term liquidity, demonstrating that the company possesses more than thirteen times the current assets needed to cover its short-term liabilities. Return on Equity is -32.3% and Return on Assets is -19.3%, metrics that reveal management has not yet achieved profitability and that the company's assets are currently generating negative returns due to ongoing development costs.
Avaliação de valorização
The trailing twelve months P/E ratio is N/A due to negative earnings, while the forward P/E is -4.11, a negative metric that implies the market is pricing in future earnings recovery or continued losses in the near term. The price-to-book ratio is 2.45, indicating that the market values the company at a 145% premium over its book value, which often reflects investor confidence in the intangible value of the proteomics platform. The price-to-sales ratio is N/A given the lack of revenue, and the EV/EBITDA is -4.78, suggesting that traditional valuation multiples are not applicable and alternative metrics must be used to assess intrinsic value. The stock has reached a 52-week high of $4.31 and a 52-week low of $0.62; without a specific current price provided in the facts, the trading position relative to this range cannot be precisely calculated, though the wide spread suggests high volatility. The beta value is 0.99, which indicates that the stock's price volatility moves in tandem with the broader market, exhibiting neither significant defensive characteristics nor aggressive outperformance relative to the S&P 500.
Growth & Income
Revenue growth and earnings growth rates are both N/A for the year-over-year period, as the company has not yet generated positive revenue to establish a historical growth trajectory. In the absence of a dividend yield, which is N/A, and a payout ratio of 0.0%, the company does not distribute income to shareholders. Instead, the firm reinvests its limited financial resources and cash reserves directly into research and development to advance the Nautilus Voyager Platform and secure regulatory approvals. The overall growth and income profile characterizes Nautilus Biotechnology as a pure-play growth stock that offers no current income distribution but relies entirely on future commercialization success to transition from a loss-making entity to a profitable revenue generator.